Musculoskeletal & joint disease

Musculoskeletal and joint disease - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Certolizumab for ankylosing spondylitis Certolizumab for psoriatic arthritis Collagenase injection (Xiapex®) for Dupuytren's contracture Dupuytren’s contracture treatment EXOGEN® low intensity pulsed ultrasound (LIPUS) bone healing system for non-union long bone fractures Hip and knee replacement surgery in obese patients (those with a body mass index of 30 or greater) Rituximab in combination with methotrexate for rheumatoid arthritis Rituximab without methotrexate for rheumatoid arthritis Tocilizumab subcutaneous injection for rheumatoid arthritis

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Rate this page